• 9553 Citations
  • 48 Scopus h-Index
20012019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Asher A Chanan Khan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 17 Similar Profiles
Multiple Myeloma Medicine & Life Sciences
B-Cell Chronic Lymphocytic Leukemia Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Waldenstrom Macroglobulinemia Medicine & Life Sciences
Thalidomide Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Dexamethasone Medicine & Life Sciences
Survival Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2001 2019

4 Citations (Scopus)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019

Wierda, W. G., Byrd, J. C., Abramson, J. S., Bilgrami, S. F., Bociek, G., Brander, D., Brown, J., Chanan Khan, A. A., Chavez, J. C., Coutre, S. E., Davis, R. S., Fletcher, C. D., Hill, B., Kahl, B. S., Kamdar, M., Kaplan, L. D., Khan, N., Kipps, T. J., Ma, S., Malek, S. & 9 others, Mato, A., Mosse, C., Neppalli, V. T., Shadman, M., Siddiqi, T., Stephens, D., Wagner, N., Dwyer, M. A. & Sundar, H., Jan 1 2019, In : JNCCN Journal of the National Comprehensive Cancer Network. 17, 1, p. 12-20 9 p.

Research output: Contribution to journalArticle

B-Cell Chronic Lymphocytic Leukemia
Lymphoma, Large B-Cell, Diffuse
Hodgkin Disease
Lymphoma
Guidelines

IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes

Fang, H., Reichard, K. K., Rabe, K. G., Hanson, C. A., Call, T. G., Ding, W. D., Kenderian, S., Muchtar, E., Schwager, S. M., Leis, J. F., Chanan Khan, A. A., Slager, S. L., Braggio, E. D., Smoley, S. A., Kay, N. E., Shanafelt, T. D., Van Dyke, D. L. & Parikh, S. A., Jan 1 2019, (Accepted/In press) In : American Journal of Hematology.

Research output: Contribution to journalArticle

B-Cell Chronic Lymphocytic Leukemia
Survival
Therapeutics
Databases
3 Citations (Scopus)

Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma

Jagannath, S., Heffner, L. T., Ailawadhi, S., Munshi, N. C., Zimmerman, T. M., Rosenblatt, J., Lonial, S., Chanan Khan, A. A., Ruehle, M., Rharbaoui, F., Haeder, T., Wartenberg-Demand, A. & Anderson, K. C., Jan 1 2019, In : Clinical Lymphoma, Myeloma and Leukemia.

Research output: Contribution to journalArticle

Multiple Myeloma
Appointments and Schedules
Neoplasms

Monoclonal antibody utilization characteristics in patients with multiple myeloma

Ailawadhi, S., Sher, T., Azzouqa, A. G., Meghji, Z., Jain, T., Jani, P., Ahmed, S., Diehl, N., Roy, V., Shah, V., Hodge, D., Ailawadhi, M., Alegria, V. R., Paulus, A., Chanan Khan, A. A. & Fonseca, R., Sep 1 2019, In : Anti-cancer drugs. 30, 8, p. 859-865 7 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Monoclonal Antibodies
Premedication
Clinical Trials
Drug Utilization
1 Citation (Scopus)

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

Stewart, A. K., Krishnan, A. Y., Singhal, S., Boccia, R. V., Patel, M. R., Niesvizky, R., Chanan Khan, A. A., Ailawadhi, S., Brumm, J., Mundt, K. E., Hong, K., McBride, J., Shon-Nguyen, Q., Xiao, Y., Ramakrishnan, V., Polson, A. G., Samineni, D., Leipold, D., Humke, E. W., McClellan, J. S. & 1 others, Berdeja, J. G., Feb 1 2019, In : Blood cancer journal. 9, 2, 17.

Research output: Contribution to journalArticle

Open Access
Multiple Myeloma
Anti-Idiotypic Antibodies
Maximum Tolerated Dose
Antibodies
Pharmaceutical Preparations